Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OTT.S133385 http://scihub22266oqcxt.onion/10.2147/OTT.S133385 C5417656!5417656!28496333     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Onco+Targets+Ther 2017 ; 10 (ä): 2349-63 Nephropedia Template TP {{tp|p=28496333|t=2017. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies |pdf=|usr=}}{{28496333}} gab.com Text Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies JO: Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=28496333 #FOAvip The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immune evasion mechanism. Blocking of the PD-1-PD-L signaling axis has recently been shown to be effective and was clinically approved in relapsed/refractory tumors such as malignant melanoma and lung cancer, but also classical Hodgkin?s lymphoma. A plethora of trials exploring PD-1 blockade in cancer are ongoing. Here, we review the role of PD-1 signaling in lymphoid malignancies, and the latest results of trials investigating PD-1 or PD-L1 blocking agents in this group of diseases. Early phase studies proved very promising, leading to the clinical approval of a PD-1 blocking agent in Hodgkin?s lymphoma, and Phase III clinical studies are either planned or ongoing in most lymphoid malignancies. Twit Text FOAVip Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies ????Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=28496333 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28496333 #FOAvip English Wikipedia <ref>{{Cite pmid|28496333}}</ref> Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies #MMPMID28496333 Ilcus C; Bagacean C; Tempescul A; Popescu C; Parvu A; Cenariu M; Bocsan C; Zdrenghea M Onco Targets Ther 2017[]; 10 (ä): 2349-63 PMID28496333show ga The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immune evasion mechanism. Blocking of the PD-1-PD-L signaling axis has recently been shown to be effective and was clinically approved in relapsed/refractory tumors such as malignant melanoma and lung cancer, but also classical Hodgkin?s lymphoma. A plethora of trials exploring PD-1 blockade in cancer are ongoing. Here, we review the role of PD-1 signaling in lymphoid malignancies, and the latest results of trials investigating PD-1 or PD-L1 blocking agents in this group of diseases. Early phase studies proved very promising, leading to the clinical approval of a PD-1 blocking agent in Hodgkin?s lymphoma, and Phase III clinical studies are either planned or ongoing in most lymphoid malignancies. äImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid mal(epmc).pdf DeepDyve Pubget Overpricing